Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports.

Abstract

Prostate cancer is the most common non-cutaneous malignancy for men. The skeleton is the most common metastatic site but, following an improvement in survival, metastases in uncommon sites are being found more frequently in clinical practice, especially brain metastases. Despite the new drugs now available for metastatic castration resistant prostate cancer, no clinical evidence exists about their effectiveness on brain metastases. We describe the clinical history of 3 patients treated with cabazitaxel plus whole brain radiotherapy. These case reports demonstrate that cabazitaxel is highly active and well tolerated in brain metastases.

• Authors: Sabino De Placido, Pasquale Rescigno, Piera Federico, Carlo Buonerba, Davide Bosso, Livio Puglia, Michela Izzo, Tania Policastro, Giuseppe Di Lorenzo
• Journal: World journal of clinical cases (World J Clin Cases) Vol. 2 Issue 6 Pg. 228-31 (Jun 16 2014) ISSN: 2307-8960 [Print] United States
• PMID: 24945013 (Publication Type: Case Reports)